UCB Psoriasis New Drug Beats Stelara

on13, UCB announced its two stage 3 clinical results of IL-17A/F antibody bimekizumab at the annual meeting of the American Association of DermatologyThe two trials, called BE VIVID and BE READY, were compared with placebo and Johnson il-12/IL-23 antibody Stelara, respectively, and resulted in 68 percent of patients with moderate to severe psoriasis who had 16 weeks of bimekizumab symptoms disappeared completely, compared with 1.2 percent of patients in the control groupIn the BE READY trial, 59% of patients with moderate to severe psoriasis completely disappeared with 16 weeks of bimekizumab symptoms, compared with 21% of patients in the Stelara grouppsoriasis is a common mass disease, with an estimated 3% of the population affected to varying degreesStelara is a neutral il-12/IL-23 shared fragment P40 antibody, the first antibody drug to target this pathway, which is already $4 billion, although it was defeated several times in head-to-head trials after the marketT-cells play an important role in the cause of psoriasis, and at first thought that IL12-induced Th1 cells were the main mediated, because the expression of the p40 subunit of IL12 in psoriasis tissue was higher than that of normal tissuesIt was later found that IL12 was not the main problem, and experiments showed that IL12 may still have a protective effect, and il23, which also uses p40, is the mastermind of psoriasisIL-23 can activate Th17 cells and secrete cytokines such as IL17, and induce keratiatiation and division, which may be one of the key steps in the onset of psoriasisBut the IL-17 is considered a trader in this system, and the real deictator is IL23In addition to activating Th17 cells, it has other psoriasis-related functions such as affecting Treg, and Abbvie and Johnson's IL-23 antibody drugs have been clinically shown to be superior to Stelara in Phase III, but the absolute number is close to the two experimental data of today's bimekizumabbut IL-17 has also been a key target for psoriasis, with Novartis's IL-17A antibody Cosentyx, Lilly's equivalent drug Taltz and the earliest-developed IL-17A receptor antibody Siliq also defeated Stelara in a controlled trial and were approved for listingSiliq then switched to Aslecon and was later sold to Valeant for several suicides in clinical trialsIl-17A is generally considered to be the subtype most related to psoriasis, IL-17F although the closest to IL-17A but how much contribution to the efficacy has been no hard data, today's trial results for the role of IL-17F provides some evidenceOf course, between different trials is not good directly compare the efficacy, to really prove the role of IL-17F also need to do with pure IL-17A antibody head-to-head test, but it is estimated that no one to do this thingpsoriasis is large, but there are many products, so although today this data is very good but this set is a bit lateIn addition to these antibody drugs new base small molecular drug PDE4 inhibitor Otezla is also a heavy drug, last year, the new base was acquired by Squip, the product was sold to Amgen The reason is that Squibb has another small molecular psoriasis drug Tyk2 inhibitors have started stage THREE clinically, may form a monopoly in the field of oral psoriasis, the previous two days referred to Nimbus also has a Tyk2 inhibitor in clinical Antibody drugs are effective, but if oral drugs have similar effects, there will be a great advantage for the use of the non-lethal disease of psoriasis Small molecule drugs that block the binding of IL-17 to its receptors have also been a hot topic, with Nuevolution, a Danish del company acquired by Amgen last year, having small molecule IL-17 blockers The original DEL company Ensemble's main asset was il-17, although UCB itself had similar small molecule projects IL17/IL17R is not only protein interaction, but also the binding force of the two is very strong, so the drug development is very difficult, so far there is no small molecule IL-17 drug into the clinic.